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INTRODUCTION
Prostate cancer is a challenging disease for both physicians and patients. It requires a
multidisciplinary team of urologists, medical oncologists, radiation oncologists, radiologists, and
pathologists. Current management options include radical prostatectomy (RP), external beam
therapy, brachytherapy, high-intensity focused ultrasound, cryotherapy, or watchful waiting (1).
Although initial management of prostate cancer is difficult, there is even more uncertainty when
patients have biochemical recurrence (BCR) prostate cancer (BCRPCa), which is described as a
rise in prostate-specific antigen (PSA) levels in patients with prostate cancer who have undergone
surgery or radiation (1). This is because with BCRPCa, the site of recurrence can be elusive.
The multidisciplinary team needs the best data possible to ascertain treatment and management
options, while the patient deserves answers on the state of his disease.
After radical prostatectomy, up to a third of patients will experience BCRPCa (1). BCRPCa has
risen in recent years and now affects, by some estimates, 25,000 men annually in the United States
(2). Spratt et al. (2) reason that this rise is largely due to the discouragement of routine PSA
screening from the US Preventative Task Force, causing an increase of men presenting with
high-risk localized cancer (2, 3). This trend has also been observed in Europe and was the impetus
for the European Association of Urology (EAU) latest policy statement to reevaluate PSA screening
(4, 5). In addition, there is<10% utilization of adjuvant radiation therapy despite support from the
American Urological Association (AUA), American Society for Radiation Oncology (ASRO), and
American Society of Clinical Oncology (ASCO) (2).
The definition of BCRPCa depends on the initial treatment strategy. Any strategy that does not
remove all prostate epithelial tissue will demonstrate a nadir in PSA values instead of the expected
undetectable PSA values seen with RP. The AUA as well as the EAU guidelines define BCR after
RP as an initial PSA value of≥0.2 ng/ml confirmed by subsequent PSA value of≥0.2 ng/ml (1). To
predict the probability of metastasis, BCR must be taken with clinical factors such as initial PSA
level, Gleason score, pathological findings after surgery, and post-BCRPCa PSA kinetics.
After confirmation of BCRPCa, imaging is vital to supply the data needed by the
multidisciplinary team to direct management. Imaging can change management in up to 70%
of patients (1, 6). The determination of local salvage therapy, systemic therapy, surveillance, or
the addition of androgen deprivation depends on confident detection (or the lack thereof) of
recurrence and distinguishing between local recurrent andmetastatic disease (7). It should be noted
that a change in management does not necessarily translate to a change in morbidity or mortality.
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Current National Comprehensive Cancer Network (NCCN)
guidelines allow consideration of a multitude of imaging
modalities (8). However, it is our opinion that the
recommendations should be streamlined to the most effective
imaging modalities available in answering the clinical question
with the highest level of confidence available. The imaging
studies with the highest positive rate at the lowest PSA can lead
to early salvage radiation therapy.
CURRENT LANDSCAPE OF IMAGING IN
BIOCHEMICAL RECURRENCE PROSTATE
CANCER
Transrectal ultrasound (TRUS) can only evaluate the prostate bed
and detects <50% of recurrence when PSA is <0.5 ng/ml (1).
Computed tomography (CT) has poor anatomical resolution in
the treated prostate bed, and unless recurrence is of substantial
size, it is of limited use for local recurrence. CT can be helpful in
evaluating for distant metastasis; however, CT has been reported
to be positive in only 14% of cases (9). Any lesion seen on Tc-
99m methyldiphosphonate (MDP) bone scintigraphy is highly
non-specific. In fact, bone scintigraphy with BCRPCa has a
positive rate of <5% when PSA is <7.0 ng/ml (10). The other
obvious limitation of bone scintigraphy is that it cannot detect
soft tissue recurrence.
The benefit of PET/CT is that it combines functional data
ascertained by the radiotracer with limited anatomical data from
the CT portion. 18F-NaF PET/CT is a bone imaging study that
detects areas of increased bone turnover similar to Tc-99mMDP,
allowing it to detect osseous metastases (11). Although 18F-NaF
PET/CT has been shown by Jadvar et al. (12) to outperform 18-
FDG PET/CT in the detection of occult osseous metastases, it has
a similar constraint as bone scintigraphy in that it is confined
to detecting osseous recurrence where other modalities can
detect both osseous and soft tissue recurrence. The true-positive
detection rate for occult osseous metastases by 18F-NaF PET/CT
is 16.2%, and the median PSA levels for positive vs. negative
PET/CT scans is reported as 4.4 and 2.9 ng/ml, respectively
(12). 18F-FDG PET/CT, making use of glucose metabolism
with a radiolabeled glucose analog, has a low sensitivity for
BCRPCa, with only 28% detection of recurrence when PSA is
<1.5 ng/ml (1). 11C-choline leverages the function of choline
in cell membranes and lipid biosynthesis. 18F- or 11C-choline
PET/CT is only of utility when PSA is >2.0 ng/ml (1). It has
been observed that when PSA is <0.4 ng/ml, 11C-choline PET
shows a dismal positive rate of only 21% (2). 18F-fluciclovine
is a leucine amino acid analog and a novel PET radiotracer
recently Food and Drug Administration (FDA) approved for
use. Prostate cancer upregulates amino acid metabolism, giving
18F-fluciclovine its effectiveness as a radiotracer. At low PSA
levels, it has a substantial positive detection rate. At PSA values
of <1.0 ng/ml, 1.0–2.0 ng/ml, and≥2.0 ng/ml, detection rates are
reported as 72.0, 83.3, and 100%, respectively (13). Additionally,
Lovec et al. (14) reported a positive rate above 50% with men
with PSA values below or equal to 0.3 ng/ml. Although the
NCCN guidelines report only a marginally better sensitivity and
specificity range for 18F-fluciclovine compared to 11C-choline,
studies comparing them head-to-head have shown that 18F-
fluciclovine is superior (8, 15). Furthermore, Nanni et al. (15)
reported the true positives at all PSA levels were generally higher
with 18F-fluciclovine than 11C-choline.
Multi-parametric magnetic resonance imaging (mpMRI) is
highly sensitive for local recurrence with its superior anatomic
and tissue resolution. A positive rate of up to 94% has been
reported with median PSA of 0.59 ng/ml (1). With respect to
its application in prostate cancer imaging, mpMRI sequences
involve various advanced sequences. The two most important
sequences include diffusion-weighted imaging (DWI), which
measures Brownian motion of water molecules within a voxel of
tissue, and dynamic contrast enhancement (DCE) T1 imaging,
which highlights vascular perfusion to tissue. DWI signal may be
degraded secondary to the blooming artifact caused by surgical
metallic clips or retained rectal air (16). Additionally, with short
tau inversion recovery (STIR) imaging and DCE T1 imaging,
osseous lesions are readily detected. In fact, MRI can detect
changes in bone marrow prior to osteoblastic response which
is needed for other types of bone-specific imaging (17). Post-
therapy scar and fibrosis either does not enhance or demonstrates
late enhancement. Malignancy, however, demonstrates early
enhancement (18). The added benefit of mpMRI is that it
can tease out local disease from focal treatment change that
often occurs from focal therapies such as cryoablation and
high-intensity focused ultrasound (18). Diagnostic CT or the
CT portion of a PET/CT cannot provide the same level of
anatomical detail of the treatment-altered prostate bed asmpMRI
of the prostate.
In patients with BCRPCa, it is imperative to deliver salvage
radiation therapy (RT) as early as possible (ideally PSA
<0.5 ng/ml). This means that finding recurrence with the lowest
possible PSA is invaluable. Of the imaging modalities available,
the ones that detect disease with the lowest PSA value are 18F-
fluciclovine PET/CT and mpMRI. 18F-fluciclovine is effective in
detecting both local recurrence and distant metastatic disease,
while mpMRI has very high utility in detecting local recurrence.
In fact, a whole-body MRI would obviate the need for bone-
specific imaging modalities given its superiority to both bone
scintigraphy and 18F-NaF PET/CT (17). Hence, it is our opinion
that there is no need for any other imaging modality except
18F-fluciclovine PET/CT combined with mpMRI, including a
whole-body sequence, for BCRPCa, and ideally, 18F-fluciclovine
PET/MRI, if available, for the added benefit of superior
osseous detection (Figure 1). This approach will give the
multidisciplinary team the structural and functional information
to make early management decisions with high confidence.
FUTURE DIRECTIONS IN BIOCHEMICAL
RECURRENCE PROSTATE CANCER
IMAGING
Molecular imaging approaches applied in the management
of BCRPCa management include prostate-specific membrane
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FIGURE 1 | Right anterior prostate bed recurrence as seen on multi-parametric MRI (mpMRI) with 18F-fluciclovine PET/CT. There is diffusion signal on calculated
b-1400 diffusion-weighted imaging (DWI) (red arrow) (A) with corresponding low apparent diffusion coefficient (ADC) values (red arrow). (B) Anatomical correlation is
noted on T2 Half-Fourier acquisition single-shot turbo spin echo (HASTE) imaging (red arrow). (C) Lesion is confirmed to contain upregulated amino acid transport,
seen in prostate cancer, in the 18F-fluciclovine image (red arrow) (D).
antigen (PSMA) radiotracers bound either to gallium (68Ga-
PSMA) or to fluoride (18F-DCFPyL). PSMA is a membrane
glycoprotein that is overexpressed by prostate cancer cells. Ga-
PSMA PET is currently undergoing Phase III trials in the US
and appears to outperform 18F-fluciclovine with a positive rate
of 73% at a PSA range as low as 0.5 to 1.0 ng/ml and a positive
rate of>50% at the remarkably low PSA range of 0.20–0.29 ng/ml
(1). It should be noted that 68Ga-PSMA is already clinically
available in Europe and outperforms 18F-fluciclovine (19). 18F-
DCFPy is a PSMA radiotracer that produces images with higher
resolution and is currently in phase II trials (2). It has been shown
to successfully identify recurrent disease and lead to a change in
management in 60% of patients and in up to 28% of patients who
had negative CT or MR findings (20). It has been shown to detect
bone metastases as accurately as 18F-NaF PET/CT but is superior
to the latter given its ability to detect non-osseous disease at low
PSA values, making it a more useful study overall (21).
BCRPCa as well as primary prostate cancer is ripe for
quantitative imaging biomarker development using radiomics
as a methodology. Radiomics may be defined as a process of
extracting quantified data from medical images as single-order
(histogram-based) and second-order (texture analysis-based)
features, which are then classified into clusters (or signatures)
that best align with an underlying pathophysiologic process
(Figure 2). Radiomic analysis performed on pretreatment
mpMRI has been shown to predict BCRPCa, which has
implications for predicting response to adjuvant therapy (22,
23). In addition, radiomic texture analysis has been shown to
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FIGURE 2 | Graphical schema of the radiomics process that involves lesion identification, drawing regions of interest, image preprocessing followed by radiomic
feature extraction and classification that provides the imaging biomarker for predicting biochemical recurrence. Reused from Fernandes et al. (28) under the Creative
Commons License.
predict biochemical relapse as well as BCRPCa-free survival
after prostatectomy [area under the curve (AUC) 0.76]
(24). Furthermore, MR radiomic signatures [using T2W and
apparent diffusion coefficient (ADC) images] can accurately
predict the response to carbon ion radiotherapy (CIRT) for
prostate cancer as well (25). Recently, radiomics has been
shown to predict Decipher score (an mRNA-based genomic
test that predicts the occurrence of prostate cancer metastasis
after radical prostatectomy) by differentiating between low and
intermediate/high scores (with an AUC of 0.92) (26, 27).
Imaging is central to BCRPCa treatment decisions.
Current practice in the US should be reformed to use
18F-fluciclovine and moving to a PSMA-based radiotracer
as currently approved in Europe once FDA approved
in the USA in conjunction with mpMRI or as PET/MR
where available. The future is bright in the fight against
BCRPCa with growing research in imaging-based
precision medicine practices including radiomics-based
imaging biomarkers.
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